Teva Pharmaceutical Industries (TEVA +20.23%) had a day on the stock market to remember on Wednesday. The drugmaker's share price enjoyed a nearly 21% rise on the day, thanks mostly to a very well-received quarterly earnings report. That increase was far more powerful than the S&P 500 index's 0.4% bump higher that trading session.
Powerful medicine
In its third quarter, Teva booked revenue of $4.48 billion. That was 3% higher year over year, and much of that growth came from leading medications like Austedo, which improved its sales by 38% year over year to $618 million, and Ajovy, sales of which were up 19% to $168 million.
Image source: Getty Images.
As for the bottom line, Teva's net income not according to generally accepted accounting principles (GAAP) rose far more robustly. It improved by 14% to $910 million, shaking out to $0.78 per share.
With those figures, Teva notched convincing beats over the average analyst forecasts. Prognosticators tracking the stock were collectively expecting it to post $4.36 billion for revenue and $0.68 per share for non-GAAP (adjusted) net profit.
NYSE: TEVA
Key Data Points
Guidance tweaks
Teva also made some adjustments to its full-year 2025 guidance. It lowered the top end of its revenue estimate by $200 million; the range now stands at $16.8 billion to $17 billion. The company, however, left its net income forecast untouched -- it remains at $2.55 to $2.65 per share for the year.
